Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World’s leading Event Organizer


15th World Congress on Cancer Therapy, Biomarkers & Clinical Research

Philadelphia, USA

Gao Fei

University of Hong Kong, China

Title: iRGD modified lipid-polymer hybrid nanoparticles loaded isoliquiritigenin to enhance anti-breast cancer effect and targeting ability


Biography: Gao Fei


To improve the poor delivery of Isoliquiritigenin (ISL), a natural anti-breast cancer compound, is essential to promote therapeutic outcome. Herein, a tumor-targeting lipid-polymer hybrid nanoparticle (NP) system modified by tumor-homing iRGD peptides has been developed to enhance ISL anti-breast cancer efficacy. The hybrid NPs were prepared by a modified single-step nanoprecipitation method to encapsulate ISL. By the preparation aspect, iRGD peptides were anchored on the surface by a post-insertion method (ISL-iRGD NPs). The stable lipid-polymer structure of ISL-iRGD NPs with high encapsulation and loading efficiency has been confirmed. By the pharmacological research aspect, the enhanced anti-breast cancer activity of ISL-iRGD NPs was conducted both in vitro and in vivo. Compared to free ISL and non-iRGD modified counterpart, ISL-iRGD NPs showed higher cytotoxicity and cell apoptosis against three types of breast cancer cells. In addition, it would attribute to the higher cellular accumulation mediated by the iRGD-integrin recognition and nano-scale effect. More importantly, based on the active tumor tissue accumulation by iRGD peptides and the prolonged in vivo circulation by the stealth nano-structure, ISL-iRGD NPs displayed higher tumor growth inhibition efficiency in 4T-1 bearing breast tumor mice models. All in all, the constructed iRGD modified lipid-polymer hybrid NPs would provide a promising drug delivery strategy to improve ISL anti-breast cancer efficacy.